BC 007

DRUG2 trials

Sponsors

Berlin Cures GmbH

Conditions

AutoantibodiesCardiomyopathy, DilatedHealthy VolunteersHeart Failure

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

CompletedNCT02955420

Berlin Cures GmbHHealthy Volunteers

Start: 2016-08-31End: 2018-05-31Target: 74Updated: 2018-07-18

Phase 2

The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

CompletedNCT04192214

Berlin Cures GmbHAutoantibodies, Cardiomyopathy, Dilated, Heart Failure

Start: 2019-03-29End: 2022-12-06Updated: 2023-04-03

Related Papers

A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects.

2020-05-0118 citations